CERo Therapeutics Holdings(CERO)
$0.00-0.00 (-10.00%)
CERO
CERo Therapeutics Holdings stock drug pipeline
$0.00
At close:-0.00 (-10.00%)
CERo Therapeutics Holdings (CERO) Drug Pipeline
500 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cyclophosphamide, Fludarabine, Mesna, Cer-1236 | Acute Myeloid Leukemia, Aml, Refractory Acute Myeloid Leukemia | Phase I | Recruiting | CER-1236 in Patients With Acute Myeloid Leukemia (AML) | Feb 14, 2025 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cyclophosphamide, Fludarabine, Mesna, Cer-1236 | Phase I | Acute Myeloid Leukemia, Aml, Refractory Acute Myeloid Leukemia | Recruiting | CER-1236 in Patients With Acute Myeloid Leukemia (AML) | Feb 14, 2025 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Cero Therapeutics Holdings, Inc. (CERO) have in its pipeline
CERo Therapeutics Holdings CERO is currently developing the following drugs: Cyclophosphamide, Fludarabine, Mesna, Cer-1236. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

